A questionnaire was widely distributed in 2011 to estimate the global prevalence of Marek's disease (MD) and gain a better understanding of current control strategies and future concerns. A total of 112 questionnaires were returned representing 116 countries from sources including national branch secretaries of the World Veterinary Poultry Association, vaccine, breeder, and production companies, as well as MD researchers from various backgrounds. Each country listed on a questionnaire was recorded as an individual entry, and on average there were 2.0 entries per country (median 1; range 1-13). All flock types were listed as having increased MD incidence during the last 10 yr in close to 50% of countries by at least one respondent, with the majority of these countries located within French-speaking Africa, Eastern Europe, East Asia, and South America. Only 18 countries (16%) indicated increasing MD incidence was likely due to higher virulent strains, while the presence of other immunosuppressive diseases was a more common explanation. Increased use of CVI988/Rispens was cited as the most likely reason for decreasing MD incidence in 49 countries (42%). In the United States, MD incidence has continued to decrease during the last 10 yr, reaching a record low in 2007 (0.0008%) as measured by leukosis condemnation rates in broilers at slaughter. However, a recent increase of leukosis condemnations in North Carolina and Pennsylvania needs to be closely monitored.

The Marek's disease virus (MDV) induces T-cell tumors in susceptible chickens. Of the 80 to 100 known MDV genes, only the MDV MEQ gene was shown to have transforming properties. Further evidence that MEQ is probably the principal oncogene in MDV came when researchers used overlapping cosmid clones of MDV and demonstrated that deleting MEQ resulted in a highly protective Marek's disease (MD) vaccine. We deleted both copies of MEQ from a bacterial artificial chromosome clone (BAC) of MDV. The virus, BACdelMEQ, was completely attenuated and did not appear to have any adverse effect on chicken body weight in MDV maternal-antibody-positive chickens, as measured at 8 wk of age. In two protection studies, BACdelMEQ efficiently protected susceptible chickens from a challenge by MDV strain 686, one of the most virulent MDV strains. In both protection studies, the BACdelMEQ protected chickens significantly better than the commercial MD vaccine, CVI988/Rispens. Only the protein-coding sequences of MEQ were deleted and all upstream and downstream regulatory sequences were left intact. Thus, BACdelMEQ has the potential to be a superior MD vaccine as well as a vector to deliver various foreign genes to poultry.

Many livestock and human vaccines are leaky because they block symptoms but do not prevent infection or onward transmission. This leakiness is concerning because it increases vaccination coverage required to prevent disease spread and can promote evolution of increased pathogen virulence. Despite leakiness, vaccination may reduce pathogen load, affecting disease transmission dynamics. However, the impacts on post-transmission disease development and infectiousness in contact individuals are unknown. Here, we use transmission experiments involving Marek disease virus (MDV) in chickens to show that vaccination with a leaky vaccine substantially reduces viral load in both vaccinated individuals and unvaccinated contact individuals they infect. Consequently, contact birds are less likely to develop disease symptoms or die, show less severe symptoms, and shed less infectious virus themselves, when infected by vaccinated birds. These results highlight that even partial vaccination with a leaky vaccine can have unforeseen positive consequences in controlling the spread and symptoms of disease.

Objective—To determine whether cattle testing positive for Mycobacterium avium subsp paratuberculosisas determined by microbial culture of feces or antibody ELISA were more likely to have false-positive responses on the caudal fold tuberculin (CFT) test or interferon-γ (IFN-γ) assay for Mycobacterium bovis than cattle testing negative for M paratuberculosis. Animals—1,043 cattle from 10 herds in Michigan. Procedure—Feces and blood samples for plasma were collected from cattle ≥ 24 months old on the day the CFT test was read. Fecal samples were submitted for microbial culture for M paratuberculosis. Plasma samples were tested for antibody against M paratuberculosis, and IFN-γ after stimulation with purified protein derivative tuberculin from M bovis or M avium. Results—Of 1,043 cattle, 180 (17.3%) had positive CFT test results (suspects) and 8 (0.8%) had positive IFN-γ assay results after stimulation with purified protein derivative tuberculin from M bovis. Forty-five (4.3%) and 115 (11.0%) cattle tested positive for M paratuberculosis as determined by microbial culture of feces and antibody ELISA, respectively. Cattle with positive responses for M paratuberculosis appeared to have an increased likelihood of false-positive results on the CFT test, although this association was not significant. Conclusions and Clinical Relevance—No significant association was detected among cattle testing positive for M paratuberculosis as determined by microbial culture of feces and antibody ELISA and positive CFT test and IFN-γ assay results for M bovis. (J Am Vet Med Assoc 2005;226:429–435)

Marek’s disease (MD) is a lymphoproliferative disease of poultry induced by Marek’s disease virus (MDV), a highly oncogenic alphaherpesvirus. Identifying the underlying genes conferring MD genetic resistance is desired for more efficacious control measures including genomic selection, which requires accurately identified genetic markers throughout the chicken genome. Hypothesizing that variants located in transcriptional regulatory regions are the main mechanism underlying this complex trait, a genome-wide association study was conducted by genotyping a ~1,000 bird MD resource population derived from experimental inbred layers with SNPs containing 1,824 previously identified allele-specific expression (ASE) SNPs in response to MDV infection as well as 3,097 random SNPs equally spaced throughout the chicken genome. Based on the calculated associations, genomic predictions were determined for 200 roosters and selected sires had their progeny tested for Marek’s disease incidence. Our analyses indicate that these ASE SNPs account for more than 83 % of the genetic variance and exhibit nearly all the highest associations. To validate these findings, 200 roosters had their genetic merit predicted from the ASE SNPs only, and the top 30 and bottom 30 ranked roosters were reciprocally mated to random hens. The resulting progeny showed that after only one generation of bidirectional selection, there was a 22 % difference in MD incidence and this approach gave a 125 % increase in accuracy compared to current pedigree-based estimates. We conclude that variation in transcriptional regulation is the major driving cause for genetic resistance to MD, and ASE SNPs identify the underlying genes and are sufficiently linked to the causative polymorphisms that they can be used for accurate genomic prediction as well as help define the underlying molecular basis. Furthermore, this approach should be applicable to other complex traits.

The serotype 1 Marek's disease virus (MDV) is the causative agent for Marek's disease (MD), a lymphoproliferative disease of chickens of great concern to the poultry industry. CVI988 (Rispens vaccine), an attenuated serotype 1 MDV, is currently the most efficacious commercially available vaccine for preventing MD. However, it is difficult to detect and differentiate CVI988 when other serotype 1 MDVs are present. To facilitate the detection of CVI988, we developed two sets of primers for a mismatch amplification mutation assay (MAMA) PCR that targeted the single nulceotide polymorphism associated with the H19 epitope of the phosphorylated protein 38 gene. The PCR was very specific. One primer set (oncogenic primers) amplified DNA from 15 different serotype 1 MDVs except CVI988. The other primer set (CVI988 primers) amplified DNA from CVI988 but not from any of the other 15 serotype 1 MDVs. A real-time PCR assay was developed using MAMA primers, and specificity and sensitivity was evaluated in vitro and in vivo. Mixtures of plasmids (CVI988 plasmid and oncogenic plasmid) at various concentrations were used to evaluate the sensitivity/specificity of MAMA primers in vitro. Both primer setswere able to amplify as little as one copy of their respective plasmid. Oncogenic primers were highly specific and only amplified CVI988 plasmid when the concentration of oncogenic plasmid was very low (1 X 10(1)) and CVI988 plasmid was very high (1 X 10(6)). Specificity of CVI988 primers was not as high because they could amplify oncogenic plasmids when the concentration of CVI988 plasmid was 1 x 10(3) and the concentration of oncogenic 1 x 10(2). Validation of MAMA primers in in vivo samples demonstrated that oncogenic primers can be used for both early diagnosis of MD in feather pulp (FP) samples collected at 3 wk of age and confirmation of MD diagnosis in tumors. CVI988 primers could be used to monitor CVI988 vaccination in samples with a low load of oncogenic MDV DNA (latently infected samples or negative) but not in samples with a high load of oncogenic MDV DNA (tumors). Our results suggest that monitoring CVI988 vaccination in FP samples collected at 1 wk of age ensures the specificity of the CVI988 primers.